These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11468181)

  • 21. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
    Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N
    Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
    Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
    Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
    Ravi R; Bedi A
    Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
    Frese S; Brunner T; Gugger M; Uduehi A; Schmid RA
    J Thorac Cardiovasc Surg; 2002 Jan; 123(1):168-74. PubMed ID: 11782771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations.
    Qin JZ; Bacon PE; Chaturvedi V; Bonish B; Nickoloff BJ
    Exp Dermatol; 2002 Dec; 11(6):573-83. PubMed ID: 12473065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.
    Deeb D; Jiang H; Gao X; Hafner MS; Wong H; Divine G; Chapman RA; Dulchavsky SA; Gautam SC
    Mol Cancer Ther; 2004 Jul; 3(7):803-12. PubMed ID: 15252141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
    He Q; Luo X; Huang Y; Sheikh MS
    Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy.
    Lincz LF; Yeh TX; Spencer A
    Leukemia; 2001 Oct; 15(10):1650-7. PubMed ID: 11587225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
    Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
    J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
    Xiang H; Fox JA; Totpal K; Aikawa M; Dupree K; Sinicropi D; Lowe J; Escandón E
    Oncogene; 2002 May; 21(22):3611-9. PubMed ID: 12032863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
    Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
    Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
    He Q; Huang Y; Sheikh MS
    Oncogene; 2004 Apr; 23(14):2554-8. PubMed ID: 14691451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.
    Varfolomeev E; Maecker H; Sharp D; Lawrence D; Renz M; Vucic D; Ashkenazi A
    J Biol Chem; 2005 Dec; 280(49):40599-608. PubMed ID: 16227629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitric Oxide Inhibits NF-κB-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance.
    Bauer JA; Lupica JA; Didonato JA; Lindner DJ
    Anticancer Res; 2020 Dec; 40(12):6751-6763. PubMed ID: 33288568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand.
    Matsuda T; Almasan A; Tomita M; Tamaki K; Saito M; Tadano M; Yagita H; Ohta T; Mori N
    J Gen Virol; 2005 Apr; 86(Pt 4):1055-1065. PubMed ID: 15784899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
    Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.